Earlier this month (July 10, 2026), the German government voted through a sweeping set of provisions set to significantly impact medical cannabis patients who have their prescriptions covered by their statutory health insurance.
Yesterday (July 29), this was published unchanged into the Federal Gazette, seeing the ban on prescribing cannabis flower through statutory health insurance take effect on 30 July with no transitional protection, even for patients whose treatment is already approved and under way.
Despite the Bundesverband Cannabis Wirtschaft (BvCW) calling for the government to refer the bill to a mediation committee (Vermittlungsausschuss), this was immediately declined by the Bundesrat on the same day the law passed, according to the chamber’s own record (BR-Drs. 411/26).
With the parliamentary route exhausted, the fight has moved to the courts, and a scramble over how the law is to be applied.
‘Double burden’ on seriously ill
Provision §31(6) SGB V (BGBl. 2026 I Nr. 228) was reworked through the legislative process between April and 10 July, and now does two things.
It removes dried flower from the special reimbursement entitlement outright, a measure which was baked into the bill early.
Later, another measure was bolted onto this already controversial cost saving bill requiring any new prescription of extracts, dronabinol or nabilone be preceded by a mandatory six-month trial of an approved cannabis-based finished medicine.
According to the Bundesverband pharmazeutischer Cannabinoidunternehmen (BPC), a pharmaceutical cannabinoid industry body, this is set to impact some 65,000 patients in established cannabis therapy reimbursed through statutory insurance.
The BPC said the law imposed a ‘double burden’ on the seriously ill, stripping a particularly vulnerable group of a proven therapy while forcing everyone else through a six-month detour. It is calling for the blanket flower exclusion to be withdrawn and for the finished-medicine priority to apply ‘only where an approved and deliverable preparation is actually available’.
Similarly, the Bund Deutscher Cannabis-Patienten (BDCan) wrote to Federal President Frank-Walter Steinmeier asking him to examine the new rules for constitutional defects before signing them into force under Article 82(1) of the Basic Law.
The association argued that the wording left it unclear whether the six-month trial applied to existing, already-authorised therapies, and warned that no approved inhalable finished medicine exists in Germany to replace flower for patients who need rapid-onset relief, including palliative cases.
‘Seriously ill people must not lose their proven therapy overnight,’ said Daniela Joachim, Chair of the BDCan. ‘This is about security of supply, and about not interrupting ongoing treatments unnecessarily.’
‘Everything in our power to overturn this law’
On 19 July, the Arbeitsgemeinschaft Cannabis als Medizin (ACM) announced that its board had resolved to file a constitutional complaint (Verfassungsbeschwerde) against the law at the Federal Constitutional Court.
The complaint will be brought by Professor Oliver Tolmein, a lawyer with a track record in cannabis test cases before Germany’s social and administrative courts.
The ACM’s chairman, Dr Franjo Grotenhermen, wrote that the legislation ‘wrongly assumes that cannabis medicines are interchangeable’, adding that this ‘is not the case’.
The association said the Deutscher Hanfverband (DHV) had pledged its support and that it would open a dedicated donation account to fund the case.
The more immediate problem is that the law takes effect before how it will work in practice has been clarified.
Because the four approved finished medicines carry narrow licences, Sativex for multiple-sclerosis spasticity, Epidyolex for certain epilepsies, Canemes for chemotherapy-related nausea and Exilby for chronic back pain, most patients treated under §31(6) have no on-label option. Any mandated trial would therefore run off-label, a route statutory insurers reimburse only in exceptional cases.
“For the majority of diseases for which cannabis is currently used under §31(6) SGB V, there is no approved ready-to-use cannabis medicine,” the medical cannabis distributor Materia Deutschland wrote on LinkedIn, warning that off-label use ‘would have to quickly advance from the exception to the rule’ if the law stands.
Pharmacies and distributors are now pressing insurers and the Medizinischer Dienst for concrete guidance on issues like when the six-month trial can be waived or shortened, how palliative care, paediatric patients, tube feeding, swallowing disorders, intolerances and contraindications are to be handled, and what documentation the medical service will require.
READ MORE…
No benefit for insurers
The amendments were passed as part of a broader cost control bill, intended to significantly reduce the financial burden of Germany’s statutory health insurance scheme.
Dr Alessandro Rossoni, co-founder and managing director of the medical cannabis wholesaler Nimbus Health, argued on LinkedIn that the state could have captured most of the savings without removing anyone from treatment, simply by repricing the flower rather than delisting it.
Hilfstaxe, the tariff that governs what pharmacies bill insurers, fixes reimbursement for cannabis flower at €9.52 per gram plus a tiered surcharge, a rate the open market has long undercut. According to Rossoni, a 40-gram monthly prescription costs a statutory insurer about €720, against roughly €210 for the same flower bought privately in the same pharmacy at the late-2025 self-payer average of €5.23 per gram.
GAmSi data, the statutory insurers’ official quarterly reporting on what the funds prescribe and spend, put combined flower-and-extract spending at roughly €205m in 2025 (per the BvCW), of which about €124.7m went on flower (per Rossoni’s analysis).
Repricing to the market rate would have cut that to around €36m, a saving of about 71%, ‘without taking therapy away from a single patient’.
Rossoni estimates that around 14,500 people rely continuously on reimbursed flower. He goes on to point out that the same tariff already ties dronabinol reimbursement to the actual pharmacy purchase price, meaning a viable market-linked model is already being used.
“Instead of a scalpel, they used a machete,” he stated.
The government defends the wider package as necessary to stabilise contribution rates against a structural funding gap it projects could reach €40bn by 2030.
Even insurers are not convinced the measure will save what the government hopes. In its response to the April draft, the GKV-Spitzenverband, the umbrella body for the statutory funds, expressly backed removing flower from reimbursement, citing the persistent lack of evidence and concerns over medicine safety and a preference for standardised, licensed cannabinoid products.
But it conceded that the roughly €130m savings target ‘will not be achievable given the expected high switch-rate to alternative supply through extracts or finished medicines’.
In essence, they are saying that the government’s €130m ‘saving’ assumes that if you stop reimbursing flower, the insurers simply stop spending that €130m. The GKV-SV points out that those patients don’t vanish, and most will switch to alternatives like extracts, or the finished medicines the new rule pushes them toward. As such the spending simply moves, it doesn’t disappear.
How the rule was added
Beyond the change itself, how the six-month extract gateway was added has proven one of the most controversial aspects of this story.
As noted above, it did not appear in the government’s original bill, which only removed flower, but entered through a coalition amendment in the Bundestag health committee on 8 July, two days before the vote.
The mechanism had been floated weeks earlier at a committee hearing on 22 June, where the then-chairman of the Federal Joint Committee (G-BA), Professor Josef Hecken, told MPs that a mandatory six-month trial of an approved finished medicine before pharmacy preparations was conceivable, and that cannabis full-extracts could be named explicitly in the law.
Hecken retired on 30 June and was succeeded by Sonja Optendrenk.
What’s next?
With the President’s signature settled, the ACM’s complaint at Karlsruhe becomes the main route to unwinding the law, but constitutional cases move slowly.
In the near term, the decisive question is whether the GKV-Spitzenverband and the Medizinischer Dienst publish binding exemption and implementation criteria before patients are forced off their reimbursed treatments.
Meanwhile, the commercial gateway for the largest patient cohort, chronic-pain patients, remains open in law but closed in practice.
The nearest on-label option for them is Exilby, a full-spectrum extract for chronic back pain from the Munich company Vertanical, which was approved in June but has yet to reach the reimbursed market.
Vertanical sets Exilby’s price for its first six months on sale before a reimbursed rate is negotiated with the statutory insurers, and patients are being funnelled onto it during precisely that window.








